Products

The indications we want to build products within

Addiction

Alcohol
Nicotine‍
Gambling
Opioids
Barbiturates
Cannabis
Internet addiction
‍

Psychiatric conditions

Depression
Bipolar disorder
Panic disorder
Social phobia
Specific phobia
Mixed anxiety/depression
Health anxiety
ADHD
Obsessive-compulsive disorder
Generalized anxiety disorder
Post-traumatic stress disorder
Bulimia
Binge eating disorder

Somatic conditions

Headache
Migraine
Tinnitus
Diabetes
Insomnia
Chronic pain
Cancer
Irritable bowel syndrome
Erectile dysfunction
Chronic fatigue
Multiple sclerosis
Obesity
COPD

Rare diseases

Polycystic Liver Disease
Pulmonary Fibrosis
Multiple Sclerosis
Cystic Fibrosis
Narcolepsy
Acromegaly
Hemophilia
Cystinosis
Myasthenia gravis
Sickle cell disease
Epilepsy

We partner with pharma to co-create, and license digital therapies that empower patients globally.

Our treatments reduce the barriers to those seeking medical treatment by providing highly effective and safe therapies targeting untreated symptoms and diseases.

Eila®

A complete smoking cessation program treating nicotine addiction

Eila® is a 12-week program for the treatment of tobacco dependence. The DTx is currently undergoing clinical trial in Germany to provide an evidence-based, clinically validated, and personalized digital therapy to patients.

In collaboration with:

Almee™

Prescription DTx to increase quality of life for PF patients.

The comprehensive DTx will provide treatment for currently undertreated symptoms associated with PF, such as low mood and anxiety, improving the patient's quality of life.

In collaboration with:

Alex – Quit Smoking

The all-inclusive digital quit smoking coach.

Currently available for download in over 150 countries globally through the Apple App Store and Google Play.

Go to alexquitsmoking.com

Use the Alex DTx Platform to launch novel digital treatments

We partner with pharma, insurance and healthcare companies in developing and launching novel DTx treatments.

Explore our DTx Platform